Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Nyxoah (NYXH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: NYXH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.28
1 Year Target Price $11.28
| 3 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -39.16% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 210.40M USD | Price to earnings Ratio - | 1Y Target Price 11.28 |
Price to earnings Ratio - | 1Y Target Price 11.28 | ||
Volume (30-day avg) 5 | Beta 0.65 | 52 Weeks Range 4.34 - 11.87 | Updated Date 12/6/2025 |
52 Weeks Range 4.34 - 11.87 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-13 | When - | Estimate -0.6832 | Actual -0.7316 |
Profitability
Profit Margin - | Operating Margin (TTM) -1235.75% |
Management Effectiveness
Return on Assets (TTM) -43.98% | Return on Equity (TTM) -107.57% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 198361019 | Price to Sales(TTM) 37.31 |
Enterprise Value 198361019 | Price to Sales(TTM) 37.31 | ||
Enterprise Value to Revenue 31.25 | Enterprise Value to EBITDA -2 | Shares Outstanding 43026460 | Shares Floating 18624465 |
Shares Outstanding 43026460 | Shares Floating 18624465 | ||
Percent Insiders 37.58 | Percent Institutions 17.62 |
Upturn AI SWOT
Nyxoah
Company Overview
History and Background
Nyxoah S.A. was founded in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. The company focuses on the development and commercialization of innovative solutions and therapies for the treatment of Obstructive Sleep Apnea (OSA). It went public in 2020.
Core Business Areas
- Therapy: The Genio system, a neurostimulation therapy for the treatment of Obstructive Sleep Apnea (OSA).
Leadership and Structure
Olivier Taelman is the CEO. The company has a board of directors with expertise in medical devices and healthcare.
Top Products and Market Share
Key Offerings
- Genio system: The Genio system is a CE-marked, patient-centered, leadless and battery-free neurostimulation therapy for OSA, activated by an external patch. Nyxoah is focused on expanding its commercial presence, particularly in Europe and the US. The market is highly competitive, with established players like Inspire Medical Systems (INSP) and CPAP (Continuous Positive Airway Pressure) manufacturers such as ResMed (RMD).
Market Dynamics
Industry Overview
The sleep apnea market is large and growing, driven by an aging population, increasing obesity rates, and greater awareness of the condition. There's a shift towards personalized and less invasive therapies.
Positioning
Nyxoah positions itself as a leader in innovative neurostimulation therapies for OSA, offering an alternative to traditional CPAP and other surgical options. Their leadless technology differentiates them from some competitors.
Total Addressable Market (TAM)
The global sleep apnea devices market is projected to reach billions of dollars. Nyxoah, with its innovative Genio system, targets a significant portion of patients who are non-compliant with or unsuitable for CPAP therapy. The total sleep apnea device market is estimated to be worth between $7 - $10 billion with further growth expected.
Upturn SWOT Analysis
Strengths
- Innovative leadless and battery-free technology
- Patient-centered therapy
- Clinically proven efficacy
- Growing commercial presence in Europe and US
Weaknesses
- Relatively small size compared to established competitors
- Limited commercial infrastructure
- Reliance on a single product (Genio)
- Requires surgical implantation.
Opportunities
- Expanding market for OSA therapies
- Increasing awareness of neurostimulation options
- Partnerships with sleep clinics and healthcare providers
- Further clinical trials to expand indications
- Reimbursement coverage improvements
Threats
- Competition from established players (ResMed, Inspire Medical Systems)
- Pricing pressures
- Regulatory hurdles
- Potential for technological disruption by new entrants
- Adverse events associated with surgical implantation
Competitors and Market Share
Key Competitors
- INSP
- RMD
Competitive Landscape
Nyxoah offers a novel leadless neurostimulation therapy, differentiating it from Inspire (INSP). However, ResMed (RMD) is a larger player with a diversified portfolio of sleep apnea solutions, including CPAP devices.
Growth Trajectory and Initiatives
Historical Growth: Nyxoah's historical growth is characterized by its R&D of Genio and subsequent commercial launches in select markets.
Future Projections: Future growth is dependent on expanding commercial operations, gaining reimbursement coverage, and continued clinical validation of Genio. Analyst estimates depend on successful penetration of the US market.
Recent Initiatives: Recent initiatives include expanding the commercial team, initiating clinical studies, and securing regulatory approvals in key markets.
Summary
Nyxoah is a smaller medical device company with an innovative leadless neurostimulation system for sleep apnea. The company is growing, but has considerable competition from much larger established players. Their product innovation gives them a competitive advantage, but they need to scale to achieve profitability. Challenges include competition and reimbursement. Success depends on expanding commercial operations and clinical validations.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nyxoah
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-07-02 | CEO & Executive Director Mr. Olivier Taelman | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 183 | Website https://www.nyxoah.com |
Full time employees 183 | Website https://www.nyxoah.com | ||
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.